The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.
Bernard Nordlinger
No relevant relationships to disclose
Halfdan Sorbye
Honoraria - Novartis; Pfizer; Roche
Research Funding - Amgen; Merck; Roche
Bengt Glimelius
No relevant relationships to disclose
Graeme John Poston
Consultant or Advisory Role - Biocompatibles; Merck Serono
Honoraria - Biocompatibles; Merck Serono
Research Funding - Biocompatibles
Peter M. Schlag
No relevant relationships to disclose
Philippe Rougier
No relevant relationships to disclose
Wolf Bechstein
No relevant relationships to disclose
John Neil Primrose
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Euan Thomas Walpole
No relevant relationships to disclose
Murielle E. Mauer
No relevant relationships to disclose
Thomas Gruenberger
Consultant or Advisory Role - Bayer; Merck Serono; Pfizer; Roche
Honoraria - Amgen; Bayer; Merck Serono; Roche
Research Funding - Amgen; Bayer; Merck Serono; Roche